184 related articles for article (PubMed ID: 23714529)
1. The role of JAK1/2 inhibitors in the treatment of chronic myeloproliferative neoplasms.
Keohane C; Mesa R; Harrison C
Am Soc Clin Oncol Educ Book; 2013; ():301-5. PubMed ID: 23714529
[TBL] [Abstract][Full Text] [Related]
2. Targeting myeloproliferative neoplasms with JAK inhibitors.
Pardanani A; Tefferi A
Curr Opin Hematol; 2011 Mar; 18(2):105-10. PubMed ID: 21245760
[TBL] [Abstract][Full Text] [Related]
3. JAK2 inhibitors and their impact in myeloproliferative neoplasms.
Geyer HL; Tibes R; Mesa RA
Hematology; 2012 Apr; 17 Suppl 1():S129-32. PubMed ID: 22507800
[TBL] [Abstract][Full Text] [Related]
4. The Next Generation of JAK Inhibitors: an Update on Fedratinib, Momelotonib, and Pacritinib.
Patel AA; Odenike O
Curr Hematol Malig Rep; 2020 Dec; 15(6):409-418. PubMed ID: 32780250
[TBL] [Abstract][Full Text] [Related]
5. How many JAK inhibitors in myelofibrosis?
Ferreira BV; Harrison C
Best Pract Res Clin Haematol; 2014 Jun; 27(2):187-95. PubMed ID: 25189729
[TBL] [Abstract][Full Text] [Related]
6. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms.
Quintás-Cardama A; Vaddi K; Liu P; Manshouri T; Li J; Scherle PA; Caulder E; Wen X; Li Y; Waeltz P; Rupar M; Burn T; Lo Y; Kelley J; Covington M; Shepard S; Rodgers JD; Haley P; Kantarjian H; Fridman JS; Verstovsek S
Blood; 2010 Apr; 115(15):3109-17. PubMed ID: 20130243
[TBL] [Abstract][Full Text] [Related]
7. Current outlook on molecular pathogenesis and treatment of myeloproliferative neoplasms.
Tibes R; Bogenberger JM; Benson KL; Mesa RA
Mol Diagn Ther; 2012 Oct; 16(5):269-83. PubMed ID: 23023734
[TBL] [Abstract][Full Text] [Related]
8. JAK2 inhibitors for myeloproliferative neoplasms: what is next?
Bose P; Verstovsek S
Blood; 2017 Jul; 130(2):115-125. PubMed ID: 28500170
[TBL] [Abstract][Full Text] [Related]
9. New generation small-molecule inhibitors in myeloproliferative neoplasms.
Passamonti F; Maffioli M; Caramazza D
Curr Opin Hematol; 2012 Mar; 19(2):117-23. PubMed ID: 22227528
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic potential of JAK2 inhibitors.
Verstovsek S
Hematology Am Soc Hematol Educ Program; 2009; ():636-42. PubMed ID: 20008249
[TBL] [Abstract][Full Text] [Related]
11. [Not Available].
Soret J; Kiladjian JJ
Bull Cancer; 2016 Jun; 103(6 Suppl 1):S29-38. PubMed ID: 27494970
[TBL] [Abstract][Full Text] [Related]
12. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study.
Harrison CN; Schaap N; Vannucchi AM; Kiladjian JJ; Tiu RV; Zachee P; Jourdan E; Winton E; Silver RT; Schouten HC; Passamonti F; Zweegman S; Talpaz M; Lager J; Shun Z; Mesa RA
Lancet Haematol; 2017 Jul; 4(7):e317-e324. PubMed ID: 28602585
[TBL] [Abstract][Full Text] [Related]
13. Ruxolitinib for the treatment of myelofibrosis.
Ostojic A; Vrhovac R; Verstovsek S
Drugs Today (Barc); 2011 Nov; 47(11):817-27. PubMed ID: 22146225
[TBL] [Abstract][Full Text] [Related]
14. The Development and Use of Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms.
Hobbs GS; Rozelle S; Mullally A
Hematol Oncol Clin North Am; 2017 Aug; 31(4):613-626. PubMed ID: 28673391
[TBL] [Abstract][Full Text] [Related]
15. JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations.
Pardanani A; Vannucchi AM; Passamonti F; Cervantes F; Barbui T; Tefferi A
Leukemia; 2011 Feb; 25(2):218-25. PubMed ID: 21079613
[TBL] [Abstract][Full Text] [Related]
16. Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial.
Mascarenhas J; Hoffman R; Talpaz M; Gerds AT; Stein B; Gupta V; Szoke A; Drummond M; Pristupa A; Granston T; Daly R; Al-Fayoumi S; Callahan JA; Singer JW; Gotlib J; Jamieson C; Harrison C; Mesa R; Verstovsek S
JAMA Oncol; 2018 May; 4(5):652-659. PubMed ID: 29522138
[TBL] [Abstract][Full Text] [Related]
17. Deregulated JAK/STAT signalling in lymphomagenesis, and its implications for the development of new targeted therapies.
Scott LM; Gandhi MK
Blood Rev; 2015 Nov; 29(6):405-15. PubMed ID: 26123794
[TBL] [Abstract][Full Text] [Related]
18. JAK2 inhibitors for myelofibrosis: why are they effective in patients with and without JAK2V617F mutation?
Santos FP; Verstovsek S
Anticancer Agents Med Chem; 2012 Nov; 12(9):1098-109. PubMed ID: 22583424
[TBL] [Abstract][Full Text] [Related]
19. Pacritinib: a new agent for the management of myelofibrosis?
Beauverd Y; McLornan DP; Harrison CN
Expert Opin Pharmacother; 2015; 16(15):2381-90. PubMed ID: 26389774
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of ruxolitinib in Asian patients with myelofibrosis.
Jung CW; Shih LY; Xiao Z; Jie J; Hou HA; Du X; Wang MC; Park S; Eom KS; Oritani K; Okamoto S; Tauchi T; Kim JS; Zhou D; Saito S; Li J; Handa H; Jianyong L; Ohishi K; Hou M; Depei W; Takenaka K; Liu T; Hu Y; Amagasaki T; Ito K; Gopalakrishna P; Akashi K
Leuk Lymphoma; 2015 Jul; 56(7):2067-74. PubMed ID: 25315076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
